Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
284 people get EBS articles and Market Currents by email alert.
Get email alerts on EBS »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
Emergent Biosolutions - Yet Another Failed BreakoutTraderMark • Thu, Feb 19, 2009 -
-
Emergent Biosolutions Acquisition Is Dead, Stock Fairly StableTraderMark • Fri, Jan 9, 2009
-
Until Proven Otherwise, Sticking with Emergent BioSolutionsTraderMark • Tue, Dec 30, 2008
-
-
Emergent BioSolutions Files Shelf RegistrationTraderMark • Thu, Nov 13, 2008
-
-
-
-
Emergent BioSolutions: Pipeline Dreams Can Become NightmaresIan Wyatt • Sun, Mar 30, 2008
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
3 Liquid Small Cap Healthcare Stocks Set For GrowthZetaKap • Thu, Sep 20, 2012 -
-
-
-
-
-
-
Novartis Could Jump $4 This SummerStock Croc • Tue, Jul 3, 2012 -
-
4 Cash Heavy Small Cap Biotech Stocks Trading Near 52-Week LowsZetaKap • Thu, Jun 14, 2012
-
-
-
-
-
-
-
Business Wire (Mon, 9:24AM)
-
Business Wire (Jun 6, 2013)
-
Business Wire (May 20, 2013)
-
Business Wire (May 9, 2013)
-
Business Wire (May 2, 2013)
-
Business Wire (Apr 30, 2013)
-
Business Wire (Apr 29, 2013)
-
Business Wire (Apr 25, 2013)
-
Business Wire (Mar 7, 2013)
-
at MarketWatch.com (Feb 26, 2013)
-
Business Wire (Feb 11, 2013)
-
Business Wire (Feb 4, 2013)
EBS vs. ETF Alternatives
Company Description
We are a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body’s immune system to prevent or treat disease. For financial reporting purposes, we operate in two principal business segments: biodefense and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 2, 4:51 PM Emergent BioSolutions (EBS): Q1 EPS of -$0.22 misses by $0.04. Revenue of $43.1M misses by $3.07M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, April 17, 12:40 PM Shares of Emergent BioSolutions (EBS +1.2%) spike midday amid reports letters sent to congressmen and the President contained the poison ricin. EBS makes the anthrax vaccine BioThrax. Comment! [On the Move, Healthcare]
- Tuesday, March 19, 8:55 AM Shares in Emergent BioSolutions (EBS), which makes the approved anthrax vaccine BioThrax, are on watch after the Presidential Commission for the Study of Bioethical Issues has recommended that testing for the vaccine be allowed on children. The issue now goes to Secretary of HealthKathleen Sebelius for her decision. Rights campaigners are opposed, as the side-effects on children are unknown. Comment! [Healthcare]
- Thursday, March 7, 4:35 PM Emergent BioSolutions (EBS): Q4 EPS of $0.44 in-line. Revenue of $94.6M misses by $0.49M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Monday, February 4, 2:33 PM Emergent Biosolutions (EBS -3%) slips after saying earlier today that Phase IIb trials of its tuberculosis vaccine candidate, MVA85A, didn't provide statistically significant protection against the disease in infants who had been vaccinated at birth with a widely used vaccine. The company said data related to the trial were published Monday in the Lancet journal. The drug also failed to meet a secondary endpoint of protecting from infection with Mycobacterium tuberculosis, the bacterium that causes tuberculosis. Comment! [Healthcare, On the Move]
- Wednesday, January 2, 10:27 AM Emergent Biosolutions (EBS +4%) gains this morning after announcing that its experimental drug TRU-016, a potential treatment for chronic lymphocytic leukemia, was designated as an orphan medicinal product by the European Commission. The drug received its orphan drug status from the FDA in the U.S. in 2011. Comment! [Healthcare, On the Move]
- Thursday, November 1, 2012, 9:46 AM Emergent BioSolutions (EBS): Q3 EPS of $0.18 beats by $0.04. Revenue of $66.6M misses by $2M. (PR) Comment! [Earnings, Healthcare]
- Thursday, August 2, 2012, 5:32 PM Emergent BioSolutions (EBS): Q2 EPS of $0.21 in-line. Revenue of $70.4M (-20% Y/Y) misses by $6M. (PR) Comment! [Earnings, Healthcare]
- Thursday, May 3, 2012, 6:11 PM Emergent BioSolutions (EBS): Q1 EPS of -$0.19 misses by $0.01. Revenue of $50.3M (+172% Y/Y) beats by $3M. (PR) Comment! [Earnings, Healthcare]
- Thursday, March 8, 2012, 5:06 PM Emergent Biosolutions (EBS): Q4 EPS of $0.78 beats by $0.06. Revenue of $108M (+4.6% Y/Y) misses by $1M. Shares +2.4% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
- Wednesday, January 11, 2012, 11:05 AM Emergent BioSolutions (EBS -0.6%) COO Daniel Abdun-Nabi lays out one of the company's biggest driver for sales at the JPMorgan HealthCare Conference, saying the threat of a biological attack on the U.S. keeps the government's need to stockpile BioThrax very high. The latest contract with the Feds provides for delivery of the drug through Q3 of 2016. (transcript) Comment! [Quick Ideas, Healthcare]
- Monday, January 9, 2012, 7:46 AM Emergent BioSolutions (EBS) provides a financial update, saying that it anticipates 2011 revenue came in at $270M-$275M and forecasting sales in 2012 will grow to $280M-$300M. Comment! [Healthcare]
- Thursday, December 29, 2011, 11:44 AM Emergent BioSolutions (EBS +4%) moves up after Caris & Co. initiates the stock with a Buy, apparently unfazed by Abbott's decision yesterday to end its venture on TRU-016 with the company. Comment! [Healthcare, On the Move]
- Wednesday, December 28, 2011, 8:28 AM Abbott Laboratories (ABT) decides to end its venture with Emergent BioSolutions (EBS) to develop and commercialize TRU-016, as the firm cites a shift in its portfolio priorities. Under the terms of the agreement, Emergent will retain worldwide rights for the development and commercialization of TRU-016 - a potential treatment of B-cell malignancies. Shares of ABT +0.7% premarket, EBS inactive. Comment! [Healthcare]
- Monday, October 3, 2011, 8:22 AM Emergent BioSolutions (EBS) rises 3.7% premarket after announcing it's won a 5-year, $1.25B deal to supply its BioThrax anthrax vaccine to the U.S. government. The firm adds BioThrax is the only vaccine licensed by the FDA to prevent anthrax infection. Comment! [Healthcare, On the Move]
- Wednesday, June 22, 2011, 9:52 AM Achillion Pharmaceuticals (ACHN +11.5%) jumps after pricing its secondary offering at $5.90, a 1.8% discount to yesterday's close. The company plans to use the $52M it raised to bring its new line of hepatitis-c drugs to market. Comment! [Healthcare, On the Move]
-
ZetaKap
3 Liquid Small Cap Healthcare Stocks Set For Growth http://bit.ly/NFfiWZ $AUXL $EBS $DEPO @ZetaKap - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
J St. Georges
Think like a man of action. Act like a man of thought. http://bit.ly/h3Xdgu/ $TIF, $EBS - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Justin M. Hall
ZIOP, NBY, EBS, ABT, PRXL, CERN, ACT, CBRX => Notable Developments and Results 12/6/10 => Rx Investors.com => http://bit.ly/c9Kc5C - View all 0 replies
-
- View all 0 replies
LATEST REPLIES